Tradestie Institutional Equity Comparison Engine
TYRA vs ANL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANL Overall Edge
ANL Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ANL (ANL) driven by superior Momentum & Technical, Options & Structure while TYRA counters with relative strength in Growth & Margin. Fundamentally, TYRA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANL at N/M Forward P/E and -123.5% operating margin (+178.1% YoY). In options structure, TYRA sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro) against ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
TYRA N/M vs ANL N/M Fwd P/E
Growth & Margin Winner
TYRA
Op Margin 0.0% vs -123.5% ยท YoY +0.0% vs +178.1%
Momentum & Technical Winner
ANL
1Y +26.8% vs +560.3% ยท 52W Pos 20% vs 56%
Options & Structure Winner
ANL
BREAKDOWN (3rd %ile IV) vs UNCLASSIFIED (N/A IV)
TYRA
NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap
$1.3B
1M Return
+6.75%
1Y Return
+26.81%
Forward P/E
N/M
Unified AI Score
32.4 / 100
SELL
Tech 25.0
Fund 46.0
Flow 69.0
Mom 50.0
ANL
US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap
$677.5M
1M Return
-9.61%
1Y Return
+560.26%
Forward P/E
N/M
Unified AI Score
48.3 / 100
HOLD
Tech 48.0
Fund 52.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
TYRA +26.81%
ANL +560.26%
Spread: +533.45 pp (ANL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
TYRA TTM Op. Margin: 0.0%
ANL TTM Op. Margin: -123.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TYRA vs ANL. Trailing 12-month operating profitability (TYRA 0.0% vs ANL -123.5%) and valuation multiples (TYRA N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TYRA | ANL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $677.5M | Larger Scale | TYRA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +178.1% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | 0.0% | -123.5% | Higher Margin | TYRA |
| Net Profit Margin Profitability | 0.0% | -124.8% | Higher Margin | TYRA |
| Return on Equity (ROE) Capital Efficiency | -34.9% | -20.2% | Higher ROE | ANL |
| 52-Week Range Position Momentum | 20% ($15โ$41) | 56% ($1โ$17) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 0.79ฮฒ ยท 49% Vol | 2.61ฮฒ ยท 79% Vol | Lower Realized Risk | TYRA |
| Unified Institutional Score Composite Signal | 32.4 / 100 (SELL) | 48.3 / 100 (HOLD) | Higher Composite | ANL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full TYRA vs ANL Buy Guide
TYRA
BREAKDOWN
76d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
ANL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither TYRA nor ANL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.